(Q36861622)

English

Phenserine

scientific article published on July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

Phenserine. (English)

1 reference

Europe PubMed Central

16 August 2017

object named as

Jochen Klein

1

0 references

language of work or name

0 references

publication date

1 July 2007

1 reference

Europe PubMed Central

16 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

16 August 2017

16

1 reference

Europe PubMed Central

16 August 2017

7

1 reference

Europe PubMed Central

16 August 2017

1087-1097

1 reference

Europe PubMed Central

16 August 2017

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Alzheimer's disease: a re-examination of the amyloid hypothesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Deciphering the molecular basis of memory failure in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Alzheimer's disease and Abeta toxicity: from top to bottom

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Genes, models and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Control of peripheral nerve myelination by the beta-secretase BACE1

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

More attention must be paid: the neurobiology of attentional effort

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinergic function and intellectual decline in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Animal models of Alzheimer's disease and evaluation of anti-dementia drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Telomerase expression prevents replicative senescence but does not fully reset mRNA expression patterns in Werner syndrome cell strains

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

The amyloid pathology progresses in a neurotransmitter-specific manner

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinergic neuropathology in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Virtues and woes of AChE alternative splicing in stress-related neuropathologies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Pharmacotherapy for Alzheimer's disease: progress and prospects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinesterases: roles in the brain during health and disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinesterase inhibitors: new roles and therapeutic alternatives

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

(R)-N-[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Pathways towards and away from Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1087

21 January 2018

Identifiers

10.1517/13543784.16.7.1087

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36861622&oldid=2087765137"